Transparent, ethical, and scientifically rigorous research powering the next generation of therapeutics across oncology, neurology, immunology, and regenerative medicine.
Multicenter, randomized, double-blind study evaluating ZENTH-O94 monotherapy versus standard chemotherapy in patients with previously treated NSCLC.
Dose-escalation study assessing safety, pharmacokinetics, and cognitive biomarkers of NeuroRegen™ in mild cognitive impairment patients.
First-in-human study evaluating the safety and tolerability of next-generation allogeneic CAR-T constructs in healthy volunteers and refractory patients.
Post-marketing surveillance registry tracking long-term cardiovascular outcomes and rare adverse events in patients treated with CardioVex™ for 5+ years.
Final analysis confirmed statistically significant improvement in disease-free survival. Data submitted for regulatory approval in multiple jurisdictions.
Transparent tracking of assets from discovery through commercialization
Our research adheres to the highest global standards for patient safety and data integrity
All trials follow International Council for Harmonisation Good Clinical Practice guidelines, with independent monitoring committees.
Every protocol is reviewed and approved by independent Institutional Review Boards or Ethics Committees prior to initiation.
Participant data is encrypted end-to-end, anonymized per GDPR/HIPAA standards, and stored on secure, audited cloud infrastructure.
We commit to publishing outcomes for all registered trials within 12 months of completion, regardless of result direction.
Whether you're a patient seeking advanced therapies, an investigator looking to host a trial site, or a sponsor exploring partnership, our medical affairs team is ready to assist.
Contact Medical Affairs →